Trial record 1 of 4 for:
CUPID
Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure (CUPID)
This study is ongoing, but not recruiting participants.
Sponsor:
Celladon Corporation
Information provided by (Responsible Party):
Celladon Corporation
ClinicalTrials.gov Identifier:
NCT00454818
First received: March 30, 2007
Last updated: February 17, 2012
Last verified: February 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is ongoing, but not recruiting participants. |
|---|---|
| Estimated Study Completion Date: | August 2012 |
| Primary Completion Date: | August 2010 (Final data collection date for primary outcome measure) |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Jessup M, Greenberg B, Mancini D, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID). A phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure [published online ahead of print June 27, 2011]. Circulation 2011. doi:10.1161/CIRCULALTIONAHA.111.022889.
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):